scispace - formally typeset
R

Robert N. Weinreb

Researcher at University of California, San Diego

Publications -  1216
Citations -  67351

Robert N. Weinreb is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Glaucoma & Intraocular pressure. The author has an hindex of 117, co-authored 1124 publications receiving 59101 citations. Previous affiliations of Robert N. Weinreb include University of Illinois at Urbana–Champaign & University of California, Berkeley.

Papers
More filters
Journal ArticleDOI

The Pathophysiology and Treatment of Glaucoma: A Review

TL;DR: Primary care physicians can play an important role in the diagnosis of glaucoma by referring patients with positive family history or with suspicious optic nerve head findings for complete ophthalmologic examination and can improve treatment outcomes by reinforcing the importance of medication adherence and persistence.
Journal ArticleDOI

Primary open-angle glaucoma.

TL;DR: Improvements in therapy consist of more effective and better-tolerated drugs to lower intraocular pressure, and more effective surgical procedures to directly treat and protect the retinal ganglion cells that are damaged in glaucoma.
Journal ArticleDOI

Primary open-angle glaucoma.

TL;DR: Primary open-angle glaucoma (POAG) is the most common type and management of POAG includes topical drug therapies and surgery to reduce IOP, although new therapies targeting neuroprotection of RGCs and axonal regeneration are under development.
Journal ArticleDOI

Evaluation of retinal nerve fiber layer, optic nerve head, and macular thickness measurements for glaucoma detection using optical coherence tomography

TL;DR: RNFL and ONH measurements had the best discriminating performance among the several Stratus OCT parameters and improved the diagnostic accuracy for glaucoma detection using this instrument.
Journal ArticleDOI

Prevalence of ocular surface disease in glaucoma patients.

TL;DR: The coexistence of OSD and the use of BAK-containing medications may impact vision-related quality of life in this patient population of glaucoma patients.